What is William Blair’s Estimate for TLX FY2025 Earnings?

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLXFree Report) – Equities research analysts at William Blair dropped their FY2025 earnings estimates for Telix Pharmaceuticals Limited American Depositary Shares in a report issued on Wednesday, March 12th. William Blair analyst A. Hsieh now anticipates that the company will earn $0.82 per share for the year, down from their prior estimate of $0.83. William Blair has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares’ current full-year earnings is $0.24 per share. William Blair also issued estimates for Telix Pharmaceuticals Limited American Depositary Shares’ FY2026 earnings at $1.05 EPS.

Separately, UBS Group increased their price objective on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, January 27th.

Read Our Latest Research Report on TLX

Telix Pharmaceuticals Limited American Depositary Shares Price Performance

Shares of TLX stock opened at $17.30 on Friday. The firm’s 50 day simple moving average is $17.47. Telix Pharmaceuticals Limited American Depositary Shares has a 12 month low of $14.01 and a 12 month high of $30.36.

About Telix Pharmaceuticals Limited American Depositary Shares

(Get Free Report)

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

See Also

Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.